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Pathological cerebrospinal fluid protein 
concentration and albumin quotient at relapse 
predicts short-term disability progression 
in multiple sclerosis: a retrospective single 
center observational study
Lara Diem* , Maxine Bürge*, Alexander Leichtle, Arsany Hakim, Andrew Chan,  
Anke Salmen, Maria-Eleptheria Evangelopoulos* and Robert Hoepner*
Abstract
Background: Blood–brain barrier dysfunction in active multiple sclerosis (MS) lesions leads 
to pathological changes of cerebrospinal fluid (CSF). Theoretically, CSF analyses could 
help to predict relapse recovery and the course of disability. In this monocentric study, we 
investigated the impact of CSF findings assessed during the first relapse of MS on the short-
term course of disability.
Methods: We performed a retrospective observational study including MS patients with 
available CSF data after onset of first MS relapse. Clinical symptoms had to be accompanied 
by gadolinium-enhanced lesion on magnetic resonance imaging. Expanded Disability 
Status Scale (EDSS) assessments at timepoint of relapse and after relapse recovery were 
studied to analyze disability. A two-step multivariate linear regression analysis adjusted for 
EDSS at spinal tab, duration of symptoms, sex, time until post relapse EDSS assessment, 
immunotherapy post relapse, and relapse treatment with glucocorticoids/plasma exchange to 
predict relapse associated disability was run.
Results: In the first step of the regression model, pathological albumin quotient (QAlb) 
[regression coefficient 0.50, 95% confidence interval (CI) (0.07–0.92), p = 0.02, n = 99] and 
CSF protein concentration [regression coefficient 0.84, 95% CI (0.33–1.35), p = 0.001, n = 99] 
predicted EDSS after relapse recovery. In the second step, the sum score of both predictors 
[range 0–2; n per value: 0 (n = 73), 1 (n = 10), 2 (n = 15)] confirmed the negative impact on course 
of disability after relapse [regression coefficient 0.38, 95% CI (0.13–0.62), p = 0.003, n = 98]. 
In this final multivariate linear regression model (p < 0.001; R2 0.34), also EDSS at lumbar 
puncture [regression coefficient 0.58, 95% CI (0.35–0.81), p < 0.001, n = 98] and time between 
symptom onset and CSF evaluation [regression coefficient 0.03, 95% CI (0.006–0.048), p = 0.01, 
n = 98] forecast subsequent disability
Discussion: Our study conducted in MS patients during first relapse confirmed that both 
increased CSF protein concentration and pathological QAlb have a negative impact on EDSS 
after relapse. As secondary finding, we identified time from symptom onset to lumbar 
puncture as predictor of disability recovery after relapse.
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Introduction
Blood–brain barrier (BBB) dysfunction in active 
multiple sclerosis (MS) lesions leads to pathologi-
cal changes of cerebrospinal fluid (CSF). 
Theoretically, CSF analyses could help to predict 
relapse recovery and the course of disability. 
Intrathecal IgG synthesis predicted disability after 
4 years, independently from immunotherapy and 
relapse activity.1 Also albumin quotient (QAlb) 
and CSF pleocytosis were previously shown to be 
associated with disease severity.2,3 In this mono-
centric study, we investigated the impact of CSF 
findings assessed during the onset relapse on the 
short-term course of disability.
Methods
The retrospective observational study (cantonal 
ethics committee Bern: #2017-01369; Amendment 
of 18.11.2019) was performed at the Department 
of Neurology, Bern University Hospital, 
Switzerland. Diagnosis of relapsing MS was in 
accordance with McDonald 2017 criteria. Patients 
(n = 143) with lumbar puncture within 3 months 
after onset of first MS relapse accompanied by 
gadolinium enhanced (Gd+) lesion on MRI and 
without additional relapses between index relapse 
and final Expanded Disability Status Scale (EDSS) 
assessment were identified between 2009 and 
2018. Patients without first (n = 3) or second 
EDSS assessment (n = 38) or >1000 erythrocytes/
µL CSF (n = 2) were excluded, leading to a cohort 
of 100 patients (Figure 1). Continuous variables 
are compared using Mann–Whitney U test/
Kruskal–Wallis test for continuous and χ2-test for 
categorical variables. Multivariate linear regression 
analysis (MvReg) with the dependent variable 
EDSS after relapse recovery was run separately for 
each dichotomized CSF finding (normal versus 
pathological). MvReg was adjusted for EDSS at 
lumbar puncture, time between symptoms onset 
and lumbar puncture, sex, time until post relapse 
EDSS assessment, immunotherapy post relapse, 
and relapse treatment with glucocorticoids/plasma 
exchange (PLEX). The identified significant 
(defined as p < 0.05 in the previous model) CSF 
predictors were used to build a sum score with the 
range from 0 to number of predictors. This score 
was integrated in the final MvReg analysis.
Results
Of the 100 patients 66 were female and the mean 
age was 34.5 years [95% confidence interval (CI) 
(32.3–36.7); n = 100]. Relapse symptoms lasted 
for 4.3 days prior to CSF analysis [mean, 95% CI 
(2.4–6.1), n = 100; Table 1]. At lumbar puncture, 
all patients were untreated, but the majority 
started disease modifying therapies (DMTs) later 
(91/100; Table 1). EDSS at relapse was 2.2 
[mean, 95% CI (2.1–2.4), n = 100], which 
decreased to 1.4 [mean, 95% CI (1.2–1.6), 
n = 100] after 0.94 years [mean, 95% CI (0.9–
1.0), n = 100]. Of 100 relapses 94 were treated 
with glucocorticoids [mean cumulative dose 
3726.6 mg; 95% CI (3314.94–4138.25), n = 94] 
and 8/100 also with PLEX. Most frequent patho-
logical CSF findings were oligoclonal bands 
(OCBs; 92/100), pleocytosis (51/100), intrathe-
cal IgG synthesis (46/99), and increased QAlb 
(25/99; Table 1). Patients with Gd+ lesions in 
cerebral and spinal magnetic resonance imaging 
(MRI) had a tendency towards increased CSF 
IgG quotient and CSF IgG synthesis compared 
with patients with isolated Gd+ lesions in cere-
bral or spinal MRI (p-value < 0.10; Table 2). 
CSF findings did not correlate with EDSS 
assessed at time of sampling (Tables 3 and 4). We 
used a two-step regression model to predict EDSS 
after relapse. In the first step, pathological QAlb 
Figure 1. Flow chart demonstrating the generation of 
the cohort.
CSF, cerebrospinal fluid; EDSS, Expanded Disability Status 
Scale.
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Table 1. Demographic, clinical, cerebrospinal fluid and MRI characteristics of MS patients at relapse.
Variable Mean 95% confidence 
interval
n  
LL UL  
Age at lumbar puncture (years) 34.5 32.3 36.7 100  
Time between symptoms onset and lumbar puncture (days) 4.3 2.4 6.1 100  
Duration between first EDSS and lumbar puncture (days) 1.9 0.3 3.6 100  
Duration between follow-up EDSS and lumbar puncture (years) 0.9 0.9 1.0 100  
Glucocorticoids i.v. (mg) 3726.6 3314.9 4138.3 94  
CSF cell count (cells/µL) 8.0 6.4 9.6 99  
CSF protein (g/L) 0.4 0.4 0.4 99  
CSF IgG (mg/L) 49.6 43.8 55.4 99  
CSF IgG quotient 4.9 4.4 5.4 99  
CSF IgG synthesis (%) 19.8 15.2 24.4 99  
CSF albumin (mg/L) 239.2 216.3 262.2 99  
CSF albumin quotient 5.7 5.2 6.2 99  
CSF glucose (mmol/L) 3.6 3.5 3.7 100  
CSF serum glucose ratio 0.6 0.6 0.7 100  
CSF lactate (mmol/L) 1.7 1.7 1.8 97  
EDSS at spinal tab 2.2 2.1 2.4 100  
Follow-up EDSS 1.4 1.2 1.6 100  
Variable Absolute 
numbers
Percentage n  
Sex (female) 66 66.0 100  
First diagnosis of MS 100 100.0 100  
Glucocorticoids i.v. 94 94.0 100  
PLEX 8 8.0 100  
Presence of Gd enhanced lesion
Any MRI 100 100 100  
Cerebral MRI 80 83.3 96  
Spinal MRI 43 58.9 73  
Cerebral and spinal MRI 23 33.3 69  
(Continued)






Prior to lumbar puncture
No immunotherapy 100 100 100  
After lumbar puncture
No immunotherapy 9 9 100  
Interferon 23 23 100  
Glatiramer acetate 9 9 100  
Teriflunomide 4 4 100  
Dimethyl fumarate 36 36 100  
Fingolimod 13 13 100  
Natalizumab 4 4 100  
Rituximab 2 2 100  
CSF findings
CSF cell count ⩾5/µL 51 51 100  
CSF/serum glucose index <0.5 8 8 100  
CSF lactate ⩾2.1 mmol/L 11 11.3 97  
CSF IgG index ⩾0.7 13 13.1 99  
CSF IgG synthesis >10% 46 46.5 99  
CSF OCB 92 92.0 100  
CSF pathological albumin quotient 25 25.3 99  
CSF protein >0.5 g/L 15 15.2 99  
Main relapse symptom
Optic neuritis 33 33 100  
Sensory 35 35 100  
Motor 3 3 100  
Sensomotor 10 10 100  
Ataxia 4 4 100  
Brainstem 14 14 100  
Psychomotor 1 1 100  
Table 1. (Continued)
(Continued)







 LL UL  
Step 1: simple models
CSF cell count ⩾5/µL −0.002 −0.38 0.38 100 0.99
CSF/serum glucose index <0.5 0.37 −0.32 1.06 100 0.29
CSF lactate ⩾2.1 mmol/L 0.13 −0.47 0.73 97 0.68
CSF IgG index ⩾0.7 0.28 −0.28 0.83 99 0.32
CSF IgG synthesis >10% 0.006 −0.39 0.40 99 0.98
CSF presence of OCBs −0.25 −0.95 0.45 100 0.48
CSF pathological albumin quotient 0.50 0.07 0.92 99 0.02
CSF protein >0.5 g/L 0.84 0.33 1.35 99 0.001
Step 2: combined models
Sum score albumin quotient and CSF protein (range 0–2) 0.38 0.13 0.62 98 0.003
EDSS at lumbar puncture 0.58 0.35 0.81 98 <0.001
Time between symptom onset and lumbar puncture (days) 0.03 0.006 0.048 98 0.01
Statistics: multivariate linear regression (MvReg) to predict EDSS after relapse. MvReg was adjusted for EDSS at spinal tab, time between 
symptoms onset and lumbar puncture, sex, time until post relapse EDSS assessment, immunotherapy post relapse, and relapse treatment 
with glucocorticoids/PLEX. A two-step model was performed with first inclusion of single CSF values within the simple model and afterwards a 
combined model including a sum score of the previously identified significant predictors. Sum score CSF albumin quotient and CSF protein was 
calculated as follows: Var (pathological albumin quotient) + Var (CSF protein >0.5 g/L) resulting in a variable with a range from 0 to 2; significant 
findings are shown in bold.
CSF, cerebrospinal fluid; EDSS, Expanded Disability Status Scale; Gd, gadolinium; LL, lower limit; MRI, magnetic resonance imaging; MS, multiple 
sclerosis; OCB, oligoclonal band; PLEX, plasma exchange therapy; UL, upper limit; Var, variable.
Table 1. (Continued)
[regression coefficient 0.50, 95% CI (0.07–0.92), 
p = 0.02, n = 99] and CSF protein concentration 
[regression coefficient 0.84, 95% CI (0.33–1.35), 
p = 0.001, n = 99] predicted EDSS after relapse 
(Table 1). In the second step, the sum score of 
both predictors [range 0–2; n per value: 0 (n = 73), 
1 (n = 10), 2 (n = 15)] confirmed the negative 
impact of these parameters on EDSS after relapse 
[regression coefficient 0.38, 95% CI (0.13–0.62), 
p = 0.003, n = 98]. In this final MvReg model 
(p < 0.001; R2 0.34), also EDSS at lumbar punc-
ture [regression coefficient 0.58, 95% CI (0.35–
0.81), p < 0.001, n = 98] and time between 
symptom onset and CSF evaluation [regression 
coefficient 0.03, 95% CI (0.006–0.048), p = 0.01, 
n = 98] forecast subsequent disability (Table 1).
Discussion
Our study conducted in MS patients during 
first relapse confirmed that both increased CSF 
protein concentration and pathological QAlb 
have a negative impact on EDSS after relapse 
whereas immune cell count or presence of 
OCBs did not predict disability levels in our 
model. Increased BBB permeability is consid-
ered a key factor of the inflammatory process as 
demonstrated in MS pathology studies, sup-
porting our findings.6
As secondary finding, we identified time from 
symptom onset to lumbar puncture as predictor of 
disability recovery after relapse. This time interval is 
possibly indicative for the start of relapse treatment, 
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Table 2. Correlation between CSF findings and gadolinium enhancement on cerebral (cMRI) and spinal (sMRI) magnetic resonance 
imaging.
Variable cMRI: gadolinium (+) sMRI: gadolinium (+) cMRI and sMRI: gadolinium (+) p-value
Mean 95% CI n Mean 95% CI n Mean 95% CI n  
LL UL LL UL LL UL
CSF cell count (cells/µL) 7.14 5.06 9.22 57 8.00 3.95 12.05 20 10.17 6.42 13.93 23 0.20
CSF protein (g/L) 0.37 0.33 0.41 56 0.38 0.32 0.43 20 0.40 0.34 0.47 23 0.60
CSF IgG (mg/L) 42.76 37.31 48.21 57 45.22 36.34 54.09 19 70.33 51.81 88.84 23 0.02
CSF IgG quotient 4.45 3.91 4.99 57 4.48 3.63 5.34 19 6.40 4.92 7.88 23 0.06
IgG synthesis (%) 16.20 10.83 21.58 57 18.38 7.13 29.64 19 29.95 18.25 41.65 23 0.10
CSF albumin (mg/L) 236.82 203.59 270.06 57 234.95 188.18 281.71 19 248.78 202.96 294.61 23 0.67
Albumin quotient 5.68 4.96 6.41 57 5.54 4.51 6.57 19 5.70 4.65 6.74 23 1.0
CSF glucose (mmol/L) 3.54 3.43 3.65 57 3.70 3.41 3.99 20 3.58 3.38 3.7 23 0.53
CSF serum glucose 
ratio
0.63 0.60 0.66 57 0.66 0.60 0.72 20 0.64 0.59 0.68 23 0.67
CSF lactate (mmol/L) 1.74 1.65 1.82 55 1.72 1.57 1.86 20 1.70 1.60 1.79 22 0.93
Statistics: Kruskal–Wallis test; significant findings are shown in bold.
CI, confidence interval; CSF, cerebrospinal fluid; LL, lower limit; UL, upper limit.
Table 3. Correlation between CSF findings and Expanded Disability Status 
Scale at time point of sampling.
Variable Correlation coefficient p-value n
CSF cell count (cells/µL) −0.11 0.27 100
CSF protein (g/L) 0.04 0.68 99
CSF IgG (mg/L) 0.02 0.82 99
CSF IgG quotient 0.02 0.88 99
IgG synthesis (%) −0.08 0.42 99
CSF albumin (mg/L) 0.004 0.97 99
Albumin quotient 0.05 0.60 99
CSF glucose (mmol/L) −0.06 0.53 100
CSF serum glucose ratio −0.16 0.10 100
CSF lactate (mmol/L) 0.17 0.09 97
Statistic: Spearman-rho test.
CSF, cerebrospinal fluid; n, number of observations.
arguing towards an early termination of inflamma-
tory processes with glucocorticoids as performed in 
94/100 patients. However, this remains speculative 
as we were not able to calculate the time interval 
from symptom onset to first glucocorticoid infusion. 
Limitations of our work are the retrospective and 
monocentric design as well as the cohort inclusion 
criteria, which focused only on those patients with 
MRI confirmed relapse defined as presence of Gd+ 
lesion on MRI. Thus our findings cannot be trans-
ferred to patients without focal disease activity on 
MRI. Since the therapy groups were heterogeneous, 
we conducted further analysis and decided to group 
the first line treatments of the European Medicines 
Agency (EMA) label (interferon, glatiramer acetate, 
dimethyl fumarate and teriflunomide) together. 
Running the analysis confirmed the predictive effect 
of our sum score variable (regression coefficient 
0.39, 95% CI 0.081–0.706, p = 0.01, n = 71). 
Further grouping on untreated patients or those 
with second line EMA label was, due to low sample 
size, not possible and should therefore be consid-
ered as a limitation of our retrospective study.
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Table 4. Magnetic resonance (MR) imaging protocol and CSF methods/pathological values.
CSF methods/pathological values
CSF cell count Sysmex Flow Cytometry (Sysmex, Horgen, Switzerland)
CSF protein (g/L) Turbidimetric method with benzethonium chloride TPUC3; Roche Cobas8000 (Roche, Basel, Switzerland)
CSF IgG (mg/L) Nephelometry IgG Siemens BNII (Siemens, Munich, Germany)
CSF albumin (mg/L) Nephelometry ALBT auf Siemens BNII (Siemens, Munich, Germany)
CSF glucose (mmol/L) Enzymatic, hexokinase method, GLUC3 (Glucose HK Gen.3) Roche Cobas8000 (Roche, Basel, Switzerland)
CSF lactate (mmol/L) ABL825 Radiometer (Radiometer Medical ApS Åkandevej Brønshøj, Denmark)
CSF analysis was performed in the ISO 17025 accredited Center of Laboratory Medicine (ZLM) of the Inselspital – Bern University Hospital 
(see table above). The following previously described cut offs were used to define pathological CSF findings: Cell Count ≥5 per ul, Protein 
Concentration >0.5 g/L, CSF/Serum Glucose Quotient < 0.5, Lactate concentration in CSF ≥ 2.1 mmol/l, (5) IGG Index ≥ 0.7 and IgG Synthesis > 
10%. Further the age adjusted upper reference value of the albumin quotient (QAlb) was calculated as suggested by Reiber et al.: QAlb= (4 + Age / 
15) * 10-3. Positivity of oligoclonal bands was defined as presence of CSF specific OCB referring to type II and III (6).
Magnetic resonance (MR) imaging protocol
MR images are acquired on 3 Tesla (T) and 1.5T MR scanners (Magnetom Verio 3T, Magnetom Trio 3T, Magnetom Avanto 1.5T and Magnetom 1.5T 
Aera, Siemens Healthcare, Erlangen, Germany) with a standardized MS protocol containing: (i) diffusion weighted imaging, (ii) 3D T1-weighted 
MPRAGE pre- and postgadobutrol i.v., (iii) dual echo T2/PD weighted imaging, (iv) 3D FLAIR imaging and (v) 2D T1-weighted imaging post gadobutrol 
i.v. All patients receive gadobutrol (Gadovist (Bayer: Leverkusen, Germany)) 0.1mL·kg−1 body weight. 
CSF, cerebrospinal fluid.
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